aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded with a mission to revolutionize precision medicine, Actio Biosciences focuses on developing therapeutics that target the shared underlying biology of both rare and common diseases. Leveraging advances in genetics, drug discovery, and data sciences, the company aims to streamline the drug development process and bring forward potent, precisely targeted treatments. Actio Biosciences is dedicated to identifying programs where biological and technical risks can be minimized, ensuring the efficient development of meaningful medicines.
Actio Biosciences boasts a team of experts in genetics and drug discovery, supported by notable investors committed to advancing precision medicine. The company's innovative approach has led to significant achievements in identifying promising therapeutic targets that address high unmet medical needs. By bridging the gap between rare and common diseases, Actio Biosciences is making a substantial impact on the healthcare landscape, offering new hope for patients through its cutting-edge treatments.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics
Technology
AI, Biotech
Tags
Biotech
Model Types
Software, Therapeutics
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Actio Biosciences founded?
Actio Biosciences was founded in 2021.
Where is Actio Biosciences's headquarters located?
Actio Biosciences's headquarters is located in San Diego, CA, US.
When was Actio Biosciences's last funding round?
Actio Biosciences's most recent funding round was for $55M (USD) in September 2023.
How many employees does Actio Biosciences have?
Actio Biosciences has 22 employees as of Feb 4, 2024.
How much has Actio Biosciences raised to-date?
As of July 05, 2023, Actio Biosciences has raised a total of $55M (USD) since Sep 12, 2023.
Add Comparison
Total Raised to Date
$55M
USD
Last Update Sep 12, 2023
Last Deal Details
$55M
USD
Sep 12, 2023
Series A
Total Employees Over Time
22
As of Feb 2024
Actio Biosciences Address
10945 Vista Sorrento Parkway
suite 150
San Diego,
California
92130
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts